Metabolic dysfunction-associated steatohepatitis (MASH)

Our proprietary network, MASH Clinical, is a global network of clinicians and investigators that includes endocrinologists, gastroenterologists, diabetologists, and general internists with connections to hospitals worldwide. They have vast experience as a group and are devoted to improving MASH (NASH) trials.

The leading experts of the MASH Think Tank meet on a regular basis to discuss the current state of the field and innovative approaches for MASH (formerly known as NASH) studies. Under Dr. Castro Cabezas’ leadership, they work to increase understanding of MASH, create expert centres for MASH clinical trials, and help provide better patient recruitment and retention rates for MASH Sponsors.

To help in the early identification of MASH patients and to improve collaboration in the screening strategy between GPs and clinicians, Julius Clinical initiated the Global Research Initiative for Patients screening on MASH (GRIPonMASH) research project. This is a multinational program in which at-risk patients are screened for MASLD and MASH (formerly known as NAFLD and NASH). Through GRIPonMASH awareness among health care professionals will increase resulting in a more efficient screening strategy for this rapidly growing clinical problem. In addition, GRIPonMASH will identify novel biomarkers facilitating early diagnosis. Julius Clinical and UMC Utrecht received an IHI grant (grant agreement ID. 101132946) for the GRIPonMASH project as from December the 1st 2023.

We are dedicated to providing fast, high-quality patient recruitment and retention rates for MASH clinical trials, Our team has years of experience and will provide a tailor-made solution that suits your trial’s exact needs.